全文获取类型
收费全文 | 98938篇 |
免费 | 6562篇 |
国内免费 | 474篇 |
专业分类
耳鼻咽喉 | 1329篇 |
儿科学 | 2492篇 |
妇产科学 | 1811篇 |
基础医学 | 11966篇 |
口腔科学 | 2310篇 |
临床医学 | 9728篇 |
内科学 | 21648篇 |
皮肤病学 | 1403篇 |
神经病学 | 9875篇 |
特种医学 | 3546篇 |
外国民族医学 | 5篇 |
外科学 | 16242篇 |
综合类 | 1083篇 |
一般理论 | 99篇 |
预防医学 | 7717篇 |
眼科学 | 1892篇 |
药学 | 6609篇 |
中国医学 | 186篇 |
肿瘤学 | 6033篇 |
出版年
2023年 | 488篇 |
2022年 | 868篇 |
2021年 | 2461篇 |
2020年 | 1402篇 |
2019年 | 2176篇 |
2018年 | 2559篇 |
2017年 | 1861篇 |
2016年 | 1947篇 |
2015年 | 2182篇 |
2014年 | 3231篇 |
2013年 | 4417篇 |
2012年 | 6786篇 |
2011年 | 6969篇 |
2010年 | 3836篇 |
2009年 | 3422篇 |
2008年 | 6007篇 |
2007年 | 6362篇 |
2006年 | 6044篇 |
2005年 | 6049篇 |
2004年 | 5706篇 |
2003年 | 5191篇 |
2002年 | 4921篇 |
2001年 | 1032篇 |
2000年 | 913篇 |
1999年 | 1058篇 |
1998年 | 1056篇 |
1997年 | 899篇 |
1996年 | 801篇 |
1995年 | 716篇 |
1994年 | 690篇 |
1993年 | 587篇 |
1992年 | 737篇 |
1991年 | 656篇 |
1990年 | 576篇 |
1989年 | 546篇 |
1988年 | 532篇 |
1987年 | 489篇 |
1986年 | 491篇 |
1985年 | 583篇 |
1984年 | 628篇 |
1983年 | 526篇 |
1982年 | 643篇 |
1981年 | 593篇 |
1980年 | 555篇 |
1979年 | 335篇 |
1978年 | 386篇 |
1977年 | 362篇 |
1975年 | 307篇 |
1974年 | 286篇 |
1973年 | 289篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
991.
Natacha Martin Anne Bergougnoux Nesrine Baatallah Benoit Chevalier Jessica Varilh David Baux Bruno Costes Pascale Fanen Caroline Raynal Isabelle Sermet-Gaudelus Emmanuelle Girodon Magali Taulan-Cadars Alexandre Hinzpeter 《Journal of cystic fibrosis》2021,20(3):464-472
BackgroundMinigenes and in silico prediction tools are commonly used to assess the impact on splicing of CFTR variants. Exon skipping is often neglected though it could impact the efficacy of targeted therapies. The aim of the study was to identify exon skipping associated with CFTR variants and to evaluate in silico predictions of seven freely available software.MethodsCFTR basal exon skipping was evaluated on endogenous mRNA extracted from non-CF nasal cells and on two CFTR minigene banks. In silico tools and minigene systems were used to evaluate the impact of CFTR exonic variants on exon skipping.ResultsData showed that out of 65 CFTR variants tested, 26 enhanced exon skipping and that in silico prediction efficacy was of 50%-66%. Some in silico tools presented predictions with a bias towards the occurrence of splicing events while others presented a bias towards the absence of splicing events (non-detection including true negatives and false negatives). Classification of exons depending on their basal exon skipping level increased prediction rates up to 80%.ConclusionThis study indicates that taking basal exon skipping into account could orientate the choice of the in silico tools to improve prediction rates. It also highlights the need to validate effects using in vitro assays or mRNA studies in patients. Eventually, it shows that variant-guided therapy should also target exon skipping associated with variants. 相似文献
992.
993.
Rabea Asleh Hilmi Alnsasra Amir Lerman Alexandros Briasoulis Naveen L. Pereira Brooks S. Edwards Takumi Toya John M. Stulak Alfredo L. Clavell Richard C. Daly Sudhir S. Kushwaha 《American journal of transplantation》2021,21(2):626-635
We have previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. We sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied. CAV progression was assessed by measuring the Δ change in plaque volume (PV) and plaque index (PI) per year using coronary intravascular ultrasound. Proteinuria was defined as Δ urine protein ≥300 mg/24 h at 1 year after conversion to SRL. Overall, 137 patients were analyzed (26% with proteinuria). Patients with proteinuria had significantly lower GFR (P = .005) but similar GFR during follow-up. Delta PV (P < .001) and Δ PI (P = .001) were significantly higher among patients with proteinuria after adjustment for baseline characteristics. Multivariate Cox regression analysis showed higher all-cause mortality (hazard ratio 3.8; P = .01) with proteinuria but similar risk of CAV-related events (P = .61). Our results indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk. 相似文献
994.
Joseph J. Alukal Talan Zhang Paul J. Thuluvath 《American journal of transplantation》2021,21(6):2211-2219
There is a paucity of data on the outcome of liver transplantation (LT) in Budd-Chiari Syndrome (BCS) patients who are listed as status 1. The objective of our study was to determine patient or graft survival following LT in status 1 BCS patients. We utilized United Network for Organ Sharing (UNOS) database to identify all adult patients (> 18 years of age) listed as status 1 with a primary diagnosis of BCS in the United States from 1998 to 2018, and analyzed their outcomes and compared it to non-status 1 BCS patients. Four hundred and forty-six patients with BCS underwent LT between 1998 and 2018, and of these 55 (12.3%) were listed as status 1. There was no difference in long-term post-liver transplant or “intention-to-treat” survival from the time of listing to death or the last day of follow-up between status 1 and non-status 1 groups. Graft and patient survival at 5 years for status 1 patients were 75% and 82%, respectively. Cox regression analysis showed that patients listed as status 1 (aHR: 0.45, p < .02) were associated with a better survival. BCS patients listed as status 1 have excellent survival following emergency LT. 相似文献
995.
Emilie Savoye Camille Legeai Julien Branchereau Samuel Gay Bruno Riou Francois Gaudez Benoit Veber Franck Bruyere Gaelle Cheisson Thomas Kerforne Lionel Badet Olivier Bastien Corinne Antoine and the cDCD National Steering Committee 《American journal of transplantation》2021,21(7):2424-2436
Controlled donation after circulatory death (cDCD) is used for “extended criteria” donors with poorer kidney transplant outcomes. The French cDCD program started in 2015 and is characterized by normothermic regional perfusion, hypothermic machine perfusion, and short cold ischemia time. We compared the outcomes of kidney transplantation from cDCD and brain-dead (DBD) donors, matching cDCD and DBD kidney transplants by propensity scoring for donor and recipient characteristics. The matching process retained 442 of 499 cDCD and 809 of 6185 DBD transplantations. The DGF rate was 20% in cDCD recipients compared with 28% in DBD recipients (adjusted relative risk [aRR], 1.43; 95% confidence interval [CI] 1.12–1.82). When DBD transplants were ranked by cold ischemia time and machine perfusion use and compared with cDCD transplants, the aRR of DGF was higher for DBD transplants without machine perfusion, regardless of the cold ischemia time (aRR with cold ischemia time <18 h, 1.57; 95% CI 1.20–2.03, vs aRR with cold ischemia time ≥18 h, 1.79; 95% CI 1.31–2.44). The 1-year graft survival rate was similar in both groups. Early outcome was better for kidney transplants from cDCD than from matched DBD transplants with this French protocol. 相似文献
996.
Aurore Prunevieille Mohamed H. Babiker-Mohamed Colleen Aslami Bruno Gonzalez-Nolasco Nuala Mooney Gilles Benichou 《American journal of transplantation》2021,21(7):2583-2589
Extracellular vesicles, including exosomes, are regularly released by allogeneic cells after transplantation. Recipient antigen-presenting cells (APCs) capture these vesicles and subsequently display donor MHC molecules on their surface. Recent evidence suggests that activation of alloreactive T cells by the so-called cross-dressed APCs plays an important role in initiating the alloresponse associated with allograft rejection. On the other hand, whether allogeneic exosomes can bind to T cells on their own and activate them remains unclear. In this study, we showed that allogeneic exosomes can bind to T cells but do not stimulate them in vitro unless they are cultured with APCs. On the other hand, allogeneic exosomes activate T cells in vivo and sensitize mice to alloantigens but only when delivered in an inflammatory environment. 相似文献
997.
Tobias Veit Dieter Munker Jürgen Barton Katrin Milger Teresa Kauke Bruno Meiser Sebastian Michel Michael Zoller Hans Nitschko Oliver T. Keppler Jürgen Behr Nikolaus Kneidinger 《American journal of transplantation》2021,21(10):3449-3455
Letermovir is a new antiviral drug approved for the prophylaxis of CMV infection in allogeneic stem cell transplants. The aim of the study was to assess the therapeutic efficacy of letermovir in difficult to treat CMV infections in lung transplant recipients. All lung transplant recipients between March 2018 and August 2020, who have been treated with letermovir for ganciclovir-resistant or refractory CMV infection were included in the study and analysed retrospectively. In total, 28 patients were identified. CMV disease was present in 15 patients (53.6%). In 23 patients (82.1%), rapid response was noticed, and CMV-viral load could be significantly decreased (>1 log10) after a median of 17 [14–27] days and cleared subsequently in all of these patients. Five patients (17.9%) were classified as non-responder. Thereof, development of a mutation of the CMV UL56 terminase (UL-56-Gen: C325Y) conferring letermovir resistance could be observed in three patients (60%). Common side effects were mild and mostly of gastrointestinal nature. Mild adjustments of the immunosuppressive drugs were mandatory upon treatment initiation with letermovir. In addition to other interventions, letermovir was effective in difficult to treat CMV infections in lung transplant recipients. However, in patients with treatment failure mutation conferring letermovir, resistance should be taken into account. 相似文献
998.
999.
Cemile Nurdan Ozturk Can Ozturk Allison Soucise Nabiha Ahsan Joseph Kuhn Mary Platek Robert Lohman Wong Moon Raffi Gurunian 《Journal of plastic, reconstructive & aesthetic surgery》2021,74(3):480-485
IntroductionContralateral prophylactic mastectomy has the potential to decrease the occurrence of cancer and reduce psychological burden. However, it is known that complications after bilateral mastectomy are higher compared with unilateral mastectomy. Our goal was to evaluate outcomes of immediate breast reconstruction in patients undergoing bilateral mastectomy and to compare complication rates between therapeutic and prophylactic sides.Patients and MethodsElectronic medical records of patients with unilateral breast cancer who underwent bilateral mastectomy and immediate reconstruction with expanders were reviewed. Postoperative complications were compared between therapeutic and prophylactic mastectomy sides.ResultsSixty-two patients were analyzed. The overall complication rate after both stages was 23.9% on the therapeutic side and 16.5% on the prophylactic side. Infection was the most common complication on both sides. All infections on the prophylactic mastectomy side were successfully treated with intravenous (IV) antibiotics (salvage rate of 100%), whereas 35.7% of infected tissue expander/implants on the therapeutic mastectomy side were explanted despite treatment.ConclusionCareful counselling of patients undergoing elective contralateral prophylactic mastectomy is essential as complications can develop in either breast after reconstruction. 相似文献
1000.
Nathan Perlis Antonio Finelli Mike Lovas Alejandro Berlin Janet Papadakos Sangeet Ghai Vasiliki Bakas Shabbir Alibhai Odelia Lee Adam Badzynski David Wiljer Alexis Lund Amelia Di Meo Joseph Cafazzo Masoom Haider 《Canadian Urological Association journal》2021,15(4):108
IntroductionAs we progress to an era when patient autonomy and shared decision-making are highly valued, there is a need to also have effective patient-centered communication tools. Radiology reports are designed for clinicians and can be very technical and difficult for patients to understand. It is important for patients to understand their magnetic resonance imaging (MRI) report in order to make an informed treatment decision with their physician. Therefore, we aimed to create a patient-centered prostate MRI report to give our patients a better understanding of their clinical condition.MethodsA prototype patient-centered radiology report (PACERR) was created by identifying items to include based on opinions sought from a group of patients undergoing prostate MRI and medical experts. Data was collected in semi-structured interviews using a salient belief question. A prototype PACERR was created in collaboration with human factors engineering and design, medical imaging, biomedical informatics, and cancer patient education groups.ResultsFifteen patients and eight experts from urology, radiation oncology, radiology, and nursing participated in this study. Patients were particularly interested to have a report with laymen terms, concise language, contextualization of values, definitions of medical terms, and next course of action. Everyone believed the report should include the risk of MRI findings actually being cancer in the subsequent biopsy.ConclusionsA prostate MRI PACERR has been developed to communicate the most important findings relevant to decision-making in prostate cancer using patient-oriented design principles. The ability of this tool to improve patient knowledge and communication will be explored. 相似文献